PhRMA’s Liz Mahar highlights her caregiver experience and the impact it’s had on how she advocates for patients. Tune in to hear her conversation with The The Arc of California, including how others can find support within the health care system: youtube.com/watch?v=2GA7N6…

Biopharmaceutical research companies provided more than $48 billion in rebates to the Medicaid program in 2022, helping to ensure patients have affordable access to lifesaving medicines. #MedicaidAwarenessMonth phrma.org/Blog/Providing…

The FDA's Accelerated Approval program enables expedited access to drugs for patients w/ serious unmet medical needs. A recent study conducted in partnership w/ PhRMA examined AA drug utilization patterns and disparities: avalere.com/insights/inequ…

A new analysis from Avalere reaffirms the accelerated approval pathway helps close gaps in care for historically disadvantaged communities. Learn more: bit.ly/3w5Azq3

Funded by a PhRMA grant, EQBMED has engaged 14 new national & local community groups essential for the long-term sustainability of local clinical trial sites.
Discover how EQBMED prioritizes mentorship & community voices to expand community partnerships: bit.ly/3UDlcP2

ICYMI: PhRMA’s Scott LaGanga recently received the 2024 Margaret L. Hodges Leadership Award from Georgetown Lombardi for his leadership in founding the Ruesch Center Golf Tournament, which has raised $1.5 million for gastrointestinal cancer research. lombardi.georgetown.edu/news-release/g…

Intellectual property protections are critical to the research and development of new medicines and vaccines that help solve today's most pressing health care challenges. See how IP supports an innovative and sustainable future. #WorldIPDay 🌎 phrma.org/Blog/World-IP-…

Despite what recent misleading headlines suggest, the accelerated approval pathway has been a resounding success in expediting patient access to lifesaving medicines and addressing unmet medical needs. Learn more about the program here: bit.ly/3JAKMO4

Year after year, seniors have reiterated their satisfaction with Part D. Unfortunately, price setting measures like in the IRA, coupled with structural changes to the program, have put much of what has worked for patients in Part D at risk. More here: phrma.org/Blog/IRA-is-al…

'As long as PBMs have a financial incentive to push patients toward the most expensive treatments, these savings won’t fully materialize. Lawmakers must intervene to ensure that PBMs can’t continue to manipulate the drug market to the detriment of patients and their employers.'

Again, Bernie Sanders is attacking an innovative company to advance a political agenda instead of addressing the real cause of affordability challenges. Policymakers should be encouraging new medicines that improve health and avoid the most expensive parts of our health care.

Insurers and pharmacy benefit managers (PBMs) have increasingly shifted more health care costs to patients through high deductibles and coinsurance. Patients like Patty are speaking out against their abusive tactics.
#endPBMabuse

This year, voters are clear about the health care challenges they’re experiencing and the solutions they want to see. More on our blog: phrma.org/Blog/ICYMI-Vot…

Explainer: Why are US pharmacy benefit managers under fire? reut.rs/49ED8gp